Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma
Background Advanced clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer for which long-term survival rates are abysmal, though immunotherapies are showing potential. Not yet clinically vetted are bispecific T cell engagers (BTEs) that activate T cell-mediated cancer killing through...
Saved in:
| Main Authors: | Carl H June, David Weiner, Christopher A Chuckran, Daniel Park, Ryan P O’Connell, Kevin Liaw, Nils Wellhausen, Pratik S Bhojnagarwala, Devivasha Bordoloi, Nicholas Shupin, Daniel Kulp |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/6/e008733.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation
by: David B Weiner, et al.
Published: (2025-06-01) -
Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01) -
Bispecific T-cell engagers in oral cancer immunotherapy
by: Veeraraghavan Vishnu Priya
Published: (2024-06-01) -
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
by: Madelyn Espinosa-Cotton, et al.
Published: (2020-10-01) -
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
by: Melanie Märklin, et al.
Published: (2022-02-01)